www.fdanews.com/articles/183629-symbiomix-therapeutics-bacterial-vaginosis-treatment-wins-fda-nod
Symbiomix Therapeutics’ Bacterial Vaginosis Treatment Wins FDA Nod
September 21, 2017
The FDA approved Symbiomix Therapeutics’ treatment for bacterial vaginosis.
Solosec is the first single-dose oral therapy for the indication, according to the company. The approval follows a series of studies that identified only mild to moderate adverse events.
Symbiomix will launch the drug in the first quarter of 2018.